de Amorim M, Wijeratne E, Zhou S, Arnold A, Batista A, Batista Jr J
Tetrahedron. 2021; 76(43).
PMID: 33716326
PMC: 7945046.
DOI: 10.1016/j.tet.2020.131525.
Wu D, Qiu Y, Jiao Y, Qiu Z, Liu D
Front Oncol. 2020; 10:560487.
PMID: 33262941
PMC: 7686570.
DOI: 10.3389/fonc.2020.560487.
Chattopadhyay S, Ghosh S, Sarkar S, Bhadra K
Beilstein J Org Chem. 2019; 15:2524-2533.
PMID: 31728166
PMC: 6839567.
DOI: 10.3762/bjoc.15.245.
ElMarrouni A, Ritts C, Balsells J
Chem Sci. 2018; 9(32):6639-6646.
PMID: 30310596
PMC: 6115631.
DOI: 10.1039/c8sc02253d.
Liao Y, Xu L, Ou S, Edwards H, Luedtke D, Ge Y
ACS Med Chem Lett. 2018; 9(7):635-640.
PMID: 30034592
PMC: 6047035.
DOI: 10.1021/acsmedchemlett.8b00057.
Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer.
Zhang T, Li J, Ma X, Yang Y, Sun W, Jin W
EBioMedicine. 2018; 31:276-286.
PMID: 29759486
PMC: 6013969.
DOI: 10.1016/j.ebiom.2018.05.003.
Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases.
Tago T, Toyohara J
Molecules. 2018; 23(2).
PMID: 29385079
PMC: 6017260.
DOI: 10.3390/molecules23020300.
Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
Gaisina I, Tueckmantel W, Ugolkov A, Shen S, Hoffen J, Dubrovskyi O
ChemMedChem. 2015; 11(1):81-92.
PMID: 26592932
PMC: 4818591.
DOI: 10.1002/cmdc.201500456.
Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
Li J, Zhang T, Yang F, He Y, Dai F, Gao D
Br J Pharmacol. 2015; 172(15):3817-30.
PMID: 25884486
PMC: 4523338.
DOI: 10.1111/bph.13165.
An overview of naturally occurring histone deacetylase inhibitors.
Kim B, Hong J
Curr Top Med Chem. 2014; 14(24):2759-82.
PMID: 25487010
PMC: 6805157.
DOI: 10.2174/1568026615666141208105614.
Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.
Singh R, Suzuki T, Mandal T, Balsubramanian N, Haldar M, Mueller D
Biochemistry. 2014; 53(48):7445-58.
PMID: 25407689
PMC: 4263425.
DOI: 10.1021/bi500711x.
Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.
Zhang T, Chen Y, Li J, Yang F, Wu H, Dai F
Neoplasia. 2014; 16(8):665-77.
PMID: 25220594
PMC: 4234873.
DOI: 10.1016/j.neo.2014.07.009.
Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.
Nelson C, Buttrick B, Isoherranen N
Curr Top Med Chem. 2013; 13(12):1402-28.
PMID: 23688132
PMC: 4366427.
DOI: 10.2174/1568026611313120004.
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.
Tran K, Risingsong R, Royce D, Williams C, Sporn M, Pioli P
Carcinogenesis. 2012; 34(1):199-210.
PMID: 23042302
PMC: 3534195.
DOI: 10.1093/carcin/bgs319.
Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1.
Godbole A, Purushottamachar P, Martin M, Njar V
Cancer Chemother Pharmacol. 2012; 70(2):339-44.
PMID: 22580781
PMC: 3959742.
DOI: 10.1007/s00280-012-1877-z.
Design, synthesis and biological evaluation of hydroxamic acid derivatives as potential high density lipoprotein (HDL) receptor CLA-1 up-regulating agents.
Chen X, Wang L, Du Y, Wu Y, Jia X, Yang Y
Molecules. 2011; 16(11):9178-93.
PMID: 22048700
PMC: 6264451.
DOI: 10.3390/molecules16119178.
In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).
Hendricks J, Keliher E, Marinelli B, Reiner T, Weissleder R, Mazitschek R
J Med Chem. 2011; 54(15):5576-82.
PMID: 21721525
PMC: 3150598.
DOI: 10.1021/jm200620f.
The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.
Zeglis B, Pillarsetty N, Divilov V, Blasberg R, Lewis J
Nucl Med Biol. 2011; 38(5):683-96.
PMID: 21718944
PMC: 3145497.
DOI: 10.1016/j.nucmedbio.2010.12.008.
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen M, Liao W, Lu Z, Bornmann W, Hennessey V, Washington M
Cancer. 2011; 117(19):4424-38.
PMID: 21491416
PMC: 3137708.
DOI: 10.1002/cncr.26073.
Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
More S, Itsara M, Yang X, Geier E, Tadano M, Seo Y
Clin Cancer Res. 2011; 17(8):2339-49.
PMID: 21421857
PMC: 3247296.
DOI: 10.1158/1078-0432.CCR-10-2949.
